RLY-2608 Plus Fulvestrant Demonstrates Efficacy in PIK3CA-Mutated, HR+/HER2– Advanced Breast Cancer
Sarah Sammons, MD, discusses data from the phase 1 ReDiscover trial of RLY-2608 plus fulvestrant in HR-positive, HER2-negative breast cancer.
Related Articles
ctDNA-Based MRD Provides Prognostic Value for First-Line Treatment in DLBCL
PhasED-Seq–assessed ctDNA-based MRD negativity was strongly associated with improved PFS after frontline treatment in patients with DLBCL.
Ivonescimab Plus Chemo Meets PFS End Point in EGFR+ NSCLC After an EGFR TKI
Ivonescimab plus chemotherapy improved PFS vs chemotherapy alone in second- and later-line EGFR-mutated non–small cell lung cancer.
Revisit Every OncLive On Air Episode From May 2025
Read a recap of the episodes of OncLive On Air that debuted in May 2025.
Encorafenib/Cetuximab Plus Chemo Boosts PFS in BRAF V600E+ mCRC
Encorafenib plus cetuximab and mFOLFOX6 improved progression-free survival in BRAF V600E–mutated metastatic colorectal cancer.
Dr Adkins on the FDA Approval of Pembrolizumab for Neoadjuvant/Adjuvant Treatment in Resectable, Locally Advanced HNSCC
Douglas R. Adkins, MD, discusses the FDA approval of pembrolizumab for neoadjuvant and adjuvant treatment in resectable, locally advanced head and neck squamous cell carcinoma.
FDA Approves Perioperative Pembrolizumab for Resectable, Locally Advanced HNSCC
The FDA has approved perioperative pembrolizumab adjuvant radiotherapy in resectable locally advanced HNSCC.
National Fellows Forum: Lung Cancer
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Revumenib-Based Triplet Is Safe, Highly Active in Older/Unfit NMP1/KMT2A-Altered AML
Revumenib plus azacitidine and venetoclax yielded high CR rates among older patients with NPM1-mutant/KMT2A-rearranged newly diagnosed AML.
Venetoclax/DEC-C Is Potential New SOC in Newly Diagnosed AML Ineligible for Intensive Chemo
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Dr Huang on the FDA Approval of Mitomycin Intravesical Solution for Recurrent, Low-Grade, Intermediate-Risk NMIBC
William C. Huang, MD, details the FDA approval of intravesical mitomycin for recurrent, low-grade, intermediate-risk non–muscle invasive bladder cancer.